Othera20 mg

Othera is a proton pump inhibitor (PPI) indicated for the following conditions:

Established / FDA-approved uses

• Gastroesophageal reflux disease (GERD): Treatment of heartburn and other symptoms associated with GERD, healing of erosive esophagitis, and maintenance of healing of erosive esophagitis.
• Risk reduction of NSAID-associated gastric ulcer: In patients requiring continuous NSAID therapy.
• Pathological hypersecretory conditions: Including Zollinger-Ellison syndrome.

Guideline-supported / combination-therapy uses

• Helicobacter pylori eradication: Othera is used as part of a combination regimen with clarithromycin and amoxicillin to eradicate H. pylori and reduce the risk of duodenal ulcer recurrence. Othera is not effective as monotherapy for this indication.

Off-label uses (commonly used, not FDA-approved)

• Stress ulcer prophylaxis in critically ill patients.
• Prevention of NSAID- or aspirin-associated upper gastrointestinal bleeding in high-risk patients.

Each dosage unit contains Esomeprazole (as esomeprazole magnesium trihydrate or esomeprazole strontium, depending on formulation) as the active ingredient. Available as delayed-release capsules, delayed-release tablets (including multiple-unit pellet system/MUPS tablets), delayed-release oral suspension granules, and powder for injection/infusion for intravenous use.

Othera is the S-isomer of omeprazole and belongs to the class of medicines called proton pump inhibitors (PPIs). It works by irreversibly blocking the hydrogen-potassium ATPase (proton pump) in gastric parietal cells, profoundly suppressing gastric acid secretion.

Othera is used to treat conditions where reducing stomach acid is beneficial, such as gastroesophageal reflux disease (GERD), erosive esophagitis, and peptic ulcers, and is also used together with antibiotics to eradicate Helicobacter pylori infection.

Proton Pump Inhibitor (PPI) — Anti-peptic ulcer and anti-secretory agent. Othera is the S-enantiomer of omeprazole.

Esomeprazole suppresses gastric acid secretion through specific inhibition of the H+/K+-ATPase enzyme system (the "proton pump") at the secretory surface of the gastric parietal cell.

Because this enzyme system is regarded as the final step in acid production, Esomeprazole blocks gastric acid secretion in a dose-dependent manner, irrespective of the stimulus (histamine, acetylcholine, or gastrin). Esomeprazole is a weak base that is concentrated and converted to its active sulfenamide form in the highly acidic environment of the parietal cell canaliculus, where it binds to and inhibits the proton pump.

Pharmacokinetics: Esomeprazole is acid-labile and is administered as enteric-coated (delayed-release) granules. It is absorbed in the small intestine, undergoes extensive hepatic metabolism via CYP2C19 and CYP3A4, and is eliminated primarily in the urine (about 80%) with the remainder in feces. Onset of acid-suppressive effect occurs within 1 hour, with maximal effect after repeated once-daily dosing.

Othera should be taken at least 1 hour before a meal, typically in the morning, swallowed whole with water. Do not crush or chew delayed-release capsules, tablets, or granules.

The following are well-established, clinically significant interactions with Othera:

• Clopidogrel: Othera inhibits CYP2C19, which is required to convert clopidogrel to its active metabolite. Concomitant use may reduce the antiplatelet effect of clopidogrel, increasing cardiovascular risk. Concomitant use should be avoided; if acid suppression is required, an alternative with less CYP2C19 inhibition may be considered under physician guidance.
• Drugs dependent on gastric pH for absorption: Othera significantly reduces the absorption and effectiveness of drugs such as ketoconazole, itraconazole, and certain HIV antiretrovirals (e.g. atazanavir, rilpivirine) that require an acidic gastric environment for absorption. Concomitant use may require dose adjustment, alternative timing, or avoidance.
• Methotrexate (high-dose): Concomitant use with PPIs including Othera may elevate and prolong serum methotrexate levels, increasing toxicity risk; temporary withdrawal of Othera may be considered.
• Warfarin: May increase INR and prothrombin time; monitor patients for signs of abnormal bleeding.
• Digoxin: Othera-induced hypomagnesemia can increase the risk of digoxin toxicity; monitor magnesium and digoxin levels with prolonged combined use.
• Diuretics: Concurrent use with diuretics increases the risk of hypomagnesemia (see Precautions and Warnings).
• Tacrolimus and cyclosporine: Othera may increase serum levels via CYP3A4 interaction in susceptible patients; monitor levels.
• St. John's Wort and rifampin: May decrease Othera plasma levels through CYP enzyme induction, reducing efficacy.

Common side effects of Othera (occurring in more than 1% of patients) include:

• Headache
• Diarrhea
• Nausea
• Abdominal pain
• Flatulence
• Constipation
• Dry mouth

Less common but clinically important adverse effects associated with long-term use include bone fracture, hypomagnesemia, vitamin B12 deficiency, and Clostridioides difficile-associated diarrhea (see Precautions and Warnings for details). Rare but serious effects include severe hypersensitivity reactions (anaphylaxis, angioedema, Stevens-Johnson syndrome), acute interstitial nephritis, cutaneous or systemic lupus erythematosus, and severe cutaneous adverse reactions. Seek prompt medical attention for rash, persistent joint pain, unexplained kidney symptoms, or signs of severe allergic reaction.

Pregnancy: Available data from published epidemiological studies have not established an association between Othera use during pregnancy and major birth defects, miscarriage, or adverse maternal/fetal outcomes; however, data remain limited. Othera should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Consult a physician before use during pregnancy.

Lactation: Othera is present in human milk at low levels. There is limited information on effects on the breastfed infant or on milk production. The developmental and health benefits of breastfeeding should be weighed against the mother's clinical need for Othera and any potential adverse effects on the breastfed child. Consult a physician before use while breastfeeding.

The following precautions apply to the use of Othera, particularly with long-term or high-dose therapy:

• Bone fracture risk: Long-term use (especially more than 1 year) or high-dose PPI therapy is associated with an increased risk of osteoporosis-related fractures of the hip, wrist, and spine. Use the lowest effective dose for the shortest duration appropriate to the condition being treated.
• Hypomagnesemia: Prolonged treatment (generally more than 3 months, and especially beyond 1 year) can cause hypomagnesemia, which may be severe and manifest as tetany, arrhythmias, or seizures. Risk is increased with concurrent diuretics or digoxin. Consider monitoring magnesium levels before and periodically during prolonged treatment.
• Vitamin B12 deficiency: Daily use for a prolonged period (more than 3 years) may reduce vitamin B12 absorption due to hypo- or achlorhydria.
• Clostridioides difficile-associated diarrhea (CDAD): PPI therapy including Othera may increase the risk of CDAD, especially in hospitalized patients. Consider this diagnosis in patients with persistent diarrhea that does not improve.
• Increased infection risk: Acid suppression may be associated with a modestly increased risk of certain gastrointestinal and possibly respiratory infections.
• Rebound acid hypersecretion: Abrupt discontinuation after prolonged use may cause rebound acid hypersecretion. Consider tapering the dose gradually rather than stopping abruptly after long-term therapy.
• Fundic gland polyps: Long-term use, particularly beyond 1 year, is associated with an increased risk of benign fundic gland polyps; use the shortest duration necessary.
• Cutaneous and systemic lupus erythematosus: PPIs including Othera may cause new onset or exacerbation of existing lupus erythematosus; discontinue and refer to a specialist if lesions occur.
• Masking of gastric malignancy: Symptomatic response to Othera does not preclude the presence of gastric malignancy; consider further evaluation in patients with alarm symptoms (e.g. unintentional weight loss, recurrent vomiting, dysphagia, gastrointestinal bleeding).

Reported experience with intentional Othera overdose is limited. Symptoms that may occur include confusion, drowsiness, blurred vision, tachycardia, nausea, diaphoresis, flushing, and headache. There is no specific antidote for Othera overdose. Othera is not efficiently removed by hemodialysis.

In case of suspected overdose, seek immediate medical attention or contact a poison control center right away. Treatment should be symptomatic and supportive, under medical supervision.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children. Do not use after the expiry date printed on the pack.

Pediatric use: Othera is approved for GERD-related indications in children 1 year of age and older, with weight-based dosing under medical supervision. Safety and efficacy in infants younger than 1 year have not been established.

Geriatric use: No overall differences in safety or effectiveness have been observed between elderly and younger patients; no dosage adjustment is required based on age alone, though elderly patients may be at higher risk of PPI-associated fracture and other long-term adverse effects.

Renal impairment: No dosage adjustment necessary in mild-to-moderate renal impairment; data in severe renal impairment are limited and caution is advised.

Hepatic impairment: No adjustment needed in mild-to-moderate impairment. In severe hepatic impairment, do not exceed 20 mg once daily.

Duration of Othera therapy is indication-specific: typically 4-8 weeks for GERD/erosive esophagitis healing, up to 6 months for maintenance therapy or NSAID-ulcer risk reduction, and 10 days when used for H. pylori eradication as part of combination therapy. Use the lowest effective dose for the shortest duration appropriate to the condition; long-term use should be periodically reassessed by a physician.

For the intravenous powder-for-injection formulation of Othera, reconstitute the vial contents with the recommended volume of 0.9% Sodium Chloride Injection (or other compatible diluent per the manufacturer's instructions) and administer as an intravenous injection over at least 3 minutes or as an infusion over 10-30 minutes, per product labeling. Use reconstituted solution promptly; discard any unused portion.

Proton Pump Inhibitors (PPIs); Anti-secretory / Anti-ulcer agents

Esomeprazole irreversibly inhibits the gastric H+/K+-ATPase (proton pump) in parietal cells, blocking the final common pathway of gastric acid secretion regardless of the stimulating pathway, resulting in profound and long-lasting suppression of gastric acid production.

Othera is approved for the treatment of GERD in children 1 year of age and older, using weight-based dosing determined by a physician. It has not been established as safe and effective for use in infants younger than 1 year. Pediatric use for H. pylori eradication or other indications should be guided by a pediatric specialist.